References
- World Health Organization. Global Tuberculosis Report, (2021)
- J. Bruchfeld, M. Correia-Neves, and G. Källenius, Tuberculosis and HIV Coinfection, Cold Spring Harb. Perspect. Med. 5 (2015), pp. a017871–a017871. doi:https://doi.org/10.1101/cshperspect.a017871.
- M.K.N. Mazlan, M.H.D. Mohd Tazizi, R. Ahmad, M.A.A. Noh, A. Bakhtiar, H.A. Wahab, and A. Mohd Gazzali, Antituberculosis targeted drug delivery as a potential future treatment approach, Antibiotics,10 (2021), pp. 908. doi:https://doi.org/10.3390/antibiotics10080908.
- K.J. Seung, S. Keshavjee, and M.L. Rich, Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis, Cold Spring Harb. Perspect. Med. 5 (2015), pp. a017863–a017863. doi:https://doi.org/10.1101/cshperspect.a017863.
- A. Natarajan, P.M. Beena, A.V. Devnikar, and S. Mali, A systemic review on tuberculosis, Indian J. Tuberc. 67 (2020), pp. 295–311. doi:https://doi.org/10.1016/j.ijtb.2020.02.005.
- R. Dey, S. Nandi, A. Samadder, A. Saxena, and A.K. Saxena, Exploring the potential inhibition of candidate drug molecules for clinical investigation based on their docking or crystallographic analyses against M. tuberculosis enzyme targets, Curr. Top. Med. Chem. 20 (2020), pp. 2662–2680. doi:https://doi.org/10.2174/1568026620666200903163921.
- A.M. Ginsberg and M. Spigelman, Challenges in tuberculosis drug research and development, Nat. Med. 13 (2007), pp. 290–294. doi:https://doi.org/10.1038/nm0307-290.
- S. Ahmed, S. Nandi, and A.K. Saxena, An updated patent review on drugs for the treatment of tuberculosis (2018-present), Expert Opin. Ther. Pat. 32 (2022), pp. 243–260. doi:https://doi.org/10.1080/13543776.2022.2012151.
- T.S. Patil and A.S. Deshpande, Innovative strategies in the diagnosis and treatment of tuberculosis: A patent review (2014-2017), Expert Opin. Ther. Pat. 28 (2018), pp. 615–623. doi:https://doi.org/10.1080/13543776.2018.1508454.
- A.K. Saxena and A. Singh, Mycobacterial tuberculosis enzyme targets and their inhibitors, Curr. Top. Med. Chem. 19 (2019), pp. 337–355. doi:https://doi.org/10.2174/1568026619666190219105722.
- K.K. Roy, S. Singh, S.K. Sharma, R. Srivastava, V. Chaturvedi, and A.K. Saxena, Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv, Bioorg, Med. Chem. Lett. 21 (2011), pp. 5589–5593. doi:https://doi.org/10.1016/j.bmcl.2011.06.076.
- A.K. Saxena, K.K. Roy, S. Singh, S.P. Vishnoi, A. Kumar, V.K. Kashyap, L. Kremer, R. Srivastava, and B.S. Srivastava, Identification and characterisation of small-molecule inhibitors of Rv3097c-encoded lipase (LipY) of Mycobacterium tuberculosis that selectively inhibit growth of bacilli in hypoxia, Int. J. Antimicrob. Agents 42 (2013), pp. 27–35. doi:https://doi.org/10.1016/j.ijantimicag.2013.03.007.
- S.R. Khan, S. Singh, K.K. Roy, M.S. Akhtar, A.K. Saxena, and M.Y. Krishnan, Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase, Int. J. Antimicrob. Agents 41 (2013), pp. 41–46. doi:https://doi.org/10.1016/j.ijantimicag.2012.09.012.
- S. Janardhan, L. John, M. Prasanthi, V. Poroikov, and G. Narahari Sastry, A QSAR and molecular modelling study towards new lead finding: Polypharmacological approach to Mycobacterium tuberculosis, SAR QSAR Environ. Res. 28 (2017), pp. 815–832. doi:https://doi.org/10.1080/1062936x.2017.1398782.
- S. Nandi, S. Ahmed, and A.K. Saxena, Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling, SAR QSAR Environ. Res. 29 (2018), pp. 151–170. doi:https://doi.org/10.1080/1062936x.2017.1419375.
- P. Kamsri, A. Punkvang, S. Hannongbua, K. Suttisintong, P. Kittakoop, J. Spencer, A.J. Mulholland, and P. Pungpo, In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations, SAR QSAR Environ. Res. 30 (2019), pp. 775–800. doi:https://doi.org/10.1080/1062936x.2019.1658218.
- H. Verma, S. Choudhary, M. Kumar, and O. Silakari, In silico guided design of non-covalent inhibitors of DprE1: Synthesis and biological evaluation, SAR QSAR Environ. Res. 32 (2021), pp. 333–352. doi:https://doi.org/10.1080/1062936x.2021.1900390.
- Working group on new TB drugs. Clinical pipeline, 2022.
- A.S. Pym, A.H. Diacon, S.J. Tang, F. Conradie, M. Danilovits, C. Chuchottaworn, I. Vasilyeva, K. Andries, N. Bakare, T. De Marez, M. Haxaire-Theeuwes, N. Lounis, P. Meyvisch, B. Van Baelen, R.P. van Heeswijk, and B. Dannemann, Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis, Eur. Respir. J. 47 (2016), pp. 564–574. doi:https://doi.org/10.1183/13993003.00724-2015.
- R. Mahajan, Bedaquiline: First FDA-approved tuberculosis drug in 40 years, Int. J. Appl. Basic Med. Res. 3 (2013), pp. 1–2. doi:https://doi.org/10.4103/2229-516X.112228.
- S.H. Wu, H.H. Chan, H.C. Hsiao, and R. Jou, Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan, Front. Microbiol. 12 (2021), pp. 754249. doi:https://doi.org/10.3389/fmicb.2021.754249.
- G. Degiacomi, J.C. Sammartino, V. Sinigiani, P. Marra, A. Urbani, and M.R. Pasca, In vitro study of bedaquiline resistance in Mycobacterium tuberculosis multi-drug resistant clinical isolates, Front. Microbiol. 11 (2020), pp. 1–8. doi:https://doi.org/10.3389/fmicb.2020.559469.
- T.V.A. Nguyen, R.M. Anthony, A.L. Bañuls, T.V.A. Nguyen, D.H. Vu, and J.C. Alffenaar, Bedaquiline resistance: Its emergence, mechanism, and prevention, Clin. Infect. Dis. 66 (2018), pp. 1625–1630. doi:https://doi.org/10.1093/cid/cix992.
- C. Nimmo, J. Millard, K. Brien, S. Moodley, L. van Dorp, K. Lutchminarain, A. Wolf, A.D. Grant, F. Balloux, A.S. Pym, N. Padayatchi, and M. Donnell, Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients, Eur. Respir. J. 55 (2020), pp. 1902383. doi:https://doi.org/10.1183/13993003.02383-2019.
- N.A. Ismail, S.V. Omar, H. Moultrie, Z. Bhyat, F. Conradie, M. Enwerem, H. Ferreira, J. Hughes, L. Joseph, Y. Kock, V. Letsaolo, G. Maartens, G. Meintjes, D. Ngcamu, N. Okozi, X. Padanilam, A. Reuter, R. Romero, S. Schaaf, J. Te Riele, E. Variava, M. van der Meulen, F. Ismail, and N. Ndjeka, Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: A cross-sectional and longitudinal study, Lancet Infect. Dis. 22 (2021), pp. 496–506. doi:https://doi.org/10.1016/s1473-3099(21)00470-9.
- G.P. Mishra and J. Mulani, Implications of bedaquiline-resistant tuberculosis, Lancet Infect. Dis 22 (2022), pp. 166. doi:https://doi.org/10.1016/S1473-3099(22)00007-X.
- R. Girase, I. Ahmad, R. Pawara, and H. Patel, Optimizing cardio, hepato and phospholipidosis toxicity of the Bedaquiline by chemoinformatics and molecular modelling approach, SAR QSAR Environ. Res. (2022), pp. 1–21. doi:https://doi.org/10.1080/1062936x.2022.2041724.
- W. Yu and A.D. MacKerell Jr., Computer-aided drug design methods, in Antibiotics. Methods in Molecular Biology, P. Sass, ed., vol 1520, Humana Press, New York, NY, 2017, pp. 85–106. doi:https://doi.org/10.1007/978-1-4939-6634-9_5.
- H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne, The Protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242. doi:https://doi.org/10.1093/nar/28.1.235.
- A. Bortolato, M. Fanton, J.S. Mason, and S. Moro, Molecular docking methodologies, Meth. Mol. Biol. 924 (2013), pp. 339–360. doi:https://doi.org/10.1007/978-1-62703-017-5_13.
- D.B. Kitchen, H. Decornez, J.R. Furr, and J. Bajorath, Docking and scoring in virtual screening for drug discovery: Methods and applications, Nat. Rev. Drug Discov. 3 (2004), pp. 935–949. doi:https://doi.org/10.1038/nrd1549.
- N.S. Pagadala, K. Syed, and J. Tuszynski, Software for molecular docking: A review, Biophys. Rev. 9 (2017), pp. 91–102. doi:https://doi.org/10.1007/s12551-016-0247-1.
- X.-Y. Meng, H.-X. Zhang, M. Mezei, and M. Cui, Molecular docking: A powerful approach for structure-based drug discovery, Curr. Comput. Aided Drug Des. 7 (2011), pp. 146–157. doi:https://doi.org/10.2174/157340911795677602.
- R. Wang, Y. Lu, and S. Wang, Comparative evaluation of 11 scoring functions for molecular docking, J. Med. Chem. 46 (2003), pp. 2287–2303. doi:https://doi.org/10.1021/jm0203783.
- E. Yuriev, M. Agostino, and P.A. Ramsland, Challenges and advances in computational docking: 2009 in review, J. Mol. Recognit. 24 (2011), pp. 149–164. doi:https://doi.org/10.1002/jmr.1077.
- J. Ren, Y. He, W. Chen, T. Chen, G. Wang, Z. Wang, Z. Xu, X. Luo, W. Zhu, H. Jiang, J. Shen, and Y. Xu, Thermodynamic and structural characterization of halogen bonding in protein-ligand interactions: A case study of PDE5 and its inhibitors, J. Med. Chem. 57 (2014), pp. 3588–3593. doi:https://doi.org/10.1021/jm5002315.
- Y. Yang, Z. Xu, Z. Zhang, Z. Yang, Y. Liu, J. Wang, T. Cai, S. Li, K. Chen, J. Shi, and W. Zhu, Like-Charge Guanidinium pairing between ligand and receptor: An unusual interaction for drug discovery and design?, J. Phys. Chem. B 119 (2015), pp. 11988–11997. doi:https://doi.org/10.1021/acs.jpcb.5b04130.
- F. Spyrakis and C.N. Cavasotto, Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description, Arch. Biochem. Biophys. 583 (2015), pp. 105–119. doi:https://doi.org/10.1016/j.abb.2015.08.002.
- G. Wang and W. Zhu, Molecular docking for drug discovery and development: A widely used approach but far from perfect, Future Med. Chem. 8 (2016), pp. 1707–1710. doi:https://doi.org/10.4155/fmc-2016-0143.
- D. Ramírez and J. Caballero, Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target?, Int. J. Mol. Sci. 17 (2016), pp. 525. doi:https://doi.org/10.3390/ijms17040525.
- S. Singh, K.K. Roy, S.R. Khan, V.K. Kashyap, A. Sharma, S. Jaiswal, S.K. Sharma, M.Y. Krishnan, V. Chaturvedi, J. Lal, S. Sinha, A. Dasgupta, R. Srivastava, and A.K. Saxena, Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis, Bioorg. Med. Chem. 23 (2015), pp. 742–752. doi:https://doi.org/10.1016/j.bmc.2014.12.060.
- D. Kalia, K.A. Kumar, G. Meena, K.P. Sethi, R. Sharma, P. Trivedi, S.R. Khan, A.S. Verma, S.B. Singh, S.K. Sharma, K.K. Roy, R. Kant, M.Y. Krishnan, B.N. Singh, S. Sinha, V. Chaturvedi, A.K. Saxena, and D.K.J.M. Dikshit, Synthesis and anti-tubercular activity of conformationally-constrained and bisquinoline analogs of TMC207, Med. Chem. Commun. 6 (2015), pp. 1554–1563. doi:https://doi.org/10.1039/C5MD00131E.
- J. Guillemont, C. Meyer, A. Poncelet, X. Bourdrez, and K. Andries, Diarylquinolines, synthesis pathways and quantitative structure–activity relationship studies leading to the discovery of TMC207, Future Med. Chem. 3 (2011), pp. 1345–1360. doi:https://doi.org/10.4155/fmc.11.79.
- BIOVIA. Dassault Systems, Biovia Draw,19.1 Dassault Systèmes, San Diego, 2019.
- LigPrep, version 2.3. Schrödinger, LLC, New York, NY, 2009. http://www.schrodinger.com
- Schrödinger, Version 9.0, Schrödinger, LLC, New York, NY, 2009. http://www.schrodinger.com
- L. Preiss, J.D. Langer, Ö. Yildiz, L. Eckhardt-Strelau, J.E. Guillemont, A. Koul, and T. Meier, Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline, Sci. Adv. 1 (2015), pp. e1500106. doi:https://doi.org/10.1126/sciadv.1500106.
- Protein Preparation Wizard, Schrödinger Suite, Schrödinger, LLC, New York, NY, 2009. http://www.schrodinger.com
- Glide, version 5.5. Schrödinger, LLC, New York, 2009. http://www.schrodinger.com
- BIOVIA. Dassault Systems, Discovery Studio Visualizer,20.1.0, Dassault Systèmes, San Diego, 2020.
- Minitab (Version 14) [Software] 2005. Available from: http://www.minitab.com/en-US/products/minitab/default.aspx.
- E.W. Bell and Y. Zhang, DockRMSD: An open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism, J. Cheminform. 11 (2019), pp. 40. doi:https://doi.org/10.1186/s13321-019-0362-7.
- D. Ramírez and J. Caballero, Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data?, Molecules 23 (2018), pp. 1038. doi:https://doi.org/10.3390/molecules23051038.
- A.K. Saxena, J. Devillers, S.S. Bhunia, and E. Bro, Modelling inhibition of avian aromatase by azole pesticides, SAR QSAR Environ. Res. 26 (2015), pp. 757–782. doi:https://doi.org/10.1080/1062936X.2015.1090749.
- L. Chaput and L. Mouawad, Efficient conformational sampling and weak scoring in docking programs? Strategy of the wisdom of crowds, J. Cheminform. 9 (2017), pp. 37. doi:https://doi.org/10.1186/s13321-017-0227-x.
- A.K. Saxena and M. Alam, ATP synthase inhibitors as anti-tubercular agents: QSAR studies in novel substituted quinolines, Curr. Top. Med. Chem. 20 (2020), pp. 2723–2734. doi:https://doi.org/10.2174/1568026620666200903163515.